There are a number of different types and classes of medications used in the treatment of ankylosing spondylitis and related diseases. Note that different people respond to different medications with varying levels of effectiveness. Thus, it may take time to find the most effective course of treatment.
IL 12/23 Inhibitor
SAA receives no government funding and relies on the
generous donations from individuals to create and maintain the programs and
services aimed at improving the futures of the 2.7 million Americans affected
by spondylitis and its family of related diseases.
NSAIDs are the most commonly used class of medication for the treatment of pain and stiffness associated with spondyloarthritis. Ibuprofen, for instance, is a generic NSAID and is found in over-the-counter pain relievers such as Advil and Motrin.
Sometimes, high doses of NSAIDs are needed to maintain relief from the symptoms of ankylosing spondylitis and related diseases. This can pose a problem because NSAIDs can cause significant side effects, especially in the gastrointestinal tract (stomach, intestines, etc.). NSAIDs can cause reduced amounts of protective mucus in the stomach, which can result in stomach irritation. Over time, this can lead to heartburn, gastritis, and possibly ulcers and even bleeding. People can take other medications (such as antacids) to neutralize or prevent the production of excess stomach acid, help coat and protect the stomach (such as Carafate), or restore the lost mucus (such as Cytotec).
There may also be an increased risk of heart attack or stroke associated with NSAIDs, especially in people with a history of heart diseases.
A different class of NSAIDs known as COX-2 inhibitors (or COXIBs) seem to reduce the risk of gastrointestinal complications associated with traditional NSAID therapy. Celebrex (Celecoxib) is still being used to treat spondyloarthritis. Others, such as Vioxx, were pulled from the market in 2004 because of the high rate of heart attacks caused by the drug.
Although NSAIDs are commonly the first line of medications used to treat ankylosing spondylitis and related diseases, sometimes they aren't enough to control the symptoms. It is important to note, however, that it may take several weeks for some NSAIDs to show positive results. If you are considering changing medications, remember to ask your doctor about the potential benefits and side effects before you and your doctor decide whether a change in treatment is right for you.
In severe cases of ankylosing spondylitis or related disease, NSAIDs may only be partially effective or the side effects too severe to continue their use. In this case, a doctor may prescribe one of the following medications.
Sulfasalazine is one medication that can be helpful to some people with severe disease. It is known to effectively control not only pain and joint swelling from arthritis of the small joints, but also the intestinal lesions in inflammatory bowel disease. It comes in tablet form and is taken orally. Sulfasalazine is generally not utilized for spinal arthritis.
Side effects are relatively infrequent, but can include headaches, abdominal bloating, nausea, and oral ulcers. Rarely, someone being prescribed this medication can develop bone marrow suppression, which is why it is important for your doctor to regularly monitor your blood count.
Originally developed to treat cancer, this chemotherapy drug is widely used and often very effective for the treatment of rheumatoid arthritis. When prescribed for treating symptoms of spondyloarthritis, it is given in smaller doses and is generally not utilized for spinal arthritis. Methotrexate can either be taken via a self-injectable shot or orally in tablet form. When taking methotrexate, it is also necessary to take the vitamin folic acid in order to help suppress some of the possible side effects, including oral ulcers and nausea. Because of other potential serious side effects, frequent monitoring of blood counts and liver function are required. Methotrexate is strongly contraindicated in pregnant women, as it has caused birth defects and death in unborn babies.
Corticosteroids such as prednisone can be effective in relieving the inflammation of spondyloarthritis, but the side effects of long-term use can be very severe. Corticosteroid injections into the inflamed joints can provide temporary relief of the pain caused by arthritis or bursitis. In instances of Achilles' tendonitis, such injections are rarely, if ever, used because of the risk of rupturing the Achilles tendon. Also, the usefulness of corticosteroid injections to relieve the symptoms of plantar fasciitis (heel pain) is not clear.
Biologic medications are made from living organisms. The material they are made from can come from many sources, including humans, animals, and microorganisms such as bacteria or yeast.
The tumor necrosis factor alpha (TNF-α) inhibitors were the first biologic medications to have shown great promise in treating spondyloarthritis, with the first TNF inhibitor – Enbrel – being approved in 2003. These medications have been shown to be highly effective in treating not only the arthritis of the joints, but also the inflammation in the gut and eyes, as well as the spinal arthritis associated with ankylosing spondylitis and related diseases.
A serious and well known complication of the TNF inhibitors is an increased frequency of infections, along with a reduced ability to fight infections, including tuberculosis. Thus, a TB test is required before starting any of the TNF therapies. There is also a slightly increased risk of certain cancers associated with TNF inhibitors, such as lymphoma (most notably in children and teens) and skin cancers.
It should be noted that each TNF inhibitor/biologic medication works in a slightly different manner. Thus, if one does not have a positive effect, another one might.
The following TNF inhibitors are currently approved for forms of spondyloarthritis: Enbrel, Humira, Remicade, Simponi, and Cimzia.
Patient Information for CIMZIA (Certolizumab pegol)
The first and only IL-17 inhibitor approved for forms of spondyloarthritis -- specifically for ankylosing spondylitis and psoriatic arthritis -- is Cosentyx (secukinumab), which was approved in January of 2016.
Both IL-17 and TNF-α are inflammatory cytokines (cell signaling molecules) that, as the name implies, signal to activate inflammation throughout the body, modulating or altering the immune system response. Inflammatory cytokines play an important role; however, when there is an overabundance of these, as has been described in inflammatory disease, they can cause harm to the body if left unchecked.
IL-17 and TNF-α cytokines signal to specific immune cells directing them to activate inflammation, with each cytokine being responsible for signaling to a different set of cells. IL-17 and TNF inhibitor medications work by targeting their respective cytokines, obstructing their signaling pathways, and by this mechanism seek to reduce inflammation. Since secukinumab targets different cytokines than the TNF inhibitors, the hope is that this newer biologic medication will help those who haven’t responded well to the TNF inhibitors, or are not able to tolerate them.
Cosentyx carries similar risks of infections, and reduced ability to fight infections as the TNF inhibitors. It has also shown in clinical trials to exasperate inflammatory bowel disease in patients who have it, as well as bring on new cases of inflammatory bowel disease.
Patient Information for CONSENTX (secukinumab)
Ustekinumab (Stelara) works similarly to the IL-17 inhibitor, but targets different cytokines: IL-12 and IL-23. Stelara was approved in 2013 for psoriatic arthritis. Stelara also carries increased risks of infections, and reduced ability to fight infections, as well as a slightly increased risk of certain cancers.
PO Box 5872
Sherman Oaks, CA 91413
(800) 777-8189 U.S. only
or (818) 892-1616